Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in Japanese healthy adults: A Phase I study

• Autores principales: Miwa Haranaka (Autor), Makoto Yono (Autor), Hiroyuki Kishino (Autor), Rie Igarashi (Autor), Nobuyuki Oshima (Autor), Miyuki Sawata (Autor), Heather Loryn Platt (Autor)
• Formato: Libro
• Publicado: Taylor & Francis Group, 2023-08-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

V116 is an investigational 21-valent pneumococcal conjugate vaccine (PCV) to address the burden of residual adult pneumococcal disease after the introduction of pediatric PCVs into national immunization programs (NIPs) and includes serotypes highly prevalent in adult invasive pneumococcal disease (I...